Open Access

Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer (Review)

  • Authors:
    • Wei Sun
    • Shilong Fu
  • View Affiliations

  • Published online on: July 8, 2019     https://doi.org/10.3892/ol.2019.10587
  • Pages: 2173-2178
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer (OVAC) remains the most lethal gynecological malignancy; it is ranked fifth among the most common types of cancer that affect women worldwide. Several aspects of the disease, including molecular pathogenesis, epidemiology, histological subtypes, poor prognosis at early stages due to the absence of specific signs and symptoms, and curative treatments in the advanced stages are all responsible for the poor survival rate, which is evaluated to be at 5 years once the cancer is diagnosed and treatment begins. A better understanding of the pathogenesis of ovarian cancer is therefore crucial, even though unexplored pathways, in order to improve the prognosis of patients with OVAC and to develop novel therapeutic approaches. Accordingly, the tumor microenvironment, defined as the combination of proteins produced by all tumor cells and by non‑cancerous cells or the stroma, and composed of several cells, including those from the immune, inflammatory and adipose systems, as well as the mesenchymal stem, endothelial and fibroblasts cells, has recently attracted attention. Of particular interest are fibroblasts, which can be activated into cancer‑associated fibroblast (CAFs) to become a potent supporter of carcinogenesis, promoting the initiation of epithelial tumor formation, tumor growth, angiogenesis and metastasis, as well as therapeutic resistance and immunosuppression. Thus, the targeting of CAFs for early diagnosis and effective therapy warrants our attention. In this review, we discuss the mechanisms through which CAFs may affect the structure, composition and microenvironment of the ovarian tumor. We also aim to highlight important aspects of OVAC pathobiology involving CAFs, in an attempt to provide insight into novel diagnostic windows and provide new therapeutic perspectives.

References

1 

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS and Andersen MR: Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer. 109:221–227. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Borley J, Wilhelm-Benartzi C, Yazbek J, Williamson R, Bharwani N, Stewart V, Carson I, Hird E, McIndoe A, Farthing A, et al: Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 122:843–849. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG and Bodurka DC: Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 108:361–368. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Bankhead CR, Kehoe ST and Austoker J: Symptoms associated with diagnosis of ovarian cancer: A systematic review. BJOG. 112:857–865. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Borley J, Wilhelm-Benartzi C, Brown R and Ghaem-Maghami S: Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer. 107:1069–1074. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y and Ogasawara K: Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci. 106:134–142. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Ziani L, Chouaib S and Thiery J: Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. Front Immunol. 9:4142018. View Article : Google Scholar : PubMed/NCBI

8 

Willmott LJ and Fruehauf JP: Targeted therapy in ovarian cancer. J Oncol. 2010:7404722010. View Article : Google Scholar : PubMed/NCBI

9 

Sun Y: Translational horizons in the tumor microenvironment: Harnessing breakthroughs and targeting cures. Med Res Rev. 35:408–436. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Ahmed N and Stenvers KL: Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI

12 

Balkwill FR, Capasso M and Hagemann T: The tumor microenvironment at a glance. J Cell Sci. 125:5591–5596. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S and Müller R: The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol. 7:242017. View Article : Google Scholar : PubMed/NCBI

14 

Ghoneum A, Afify H, Salih Z, Kelly M and Said N: Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget. 9:22832–22849. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Cirri P and Chiarugi P: Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31:195–208. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Trivedi N, Marsh P, Goold RG, Wood-Kaczmar A and Gordon-Weeks PR: Glycogen synthase kinase-3beta phosphorylation of MAP1B at Ser1260 and Thr1265 is spatially restricted to growing axons. J Cell Sci. 118:993–1005. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Slany A, Bileck A, Muqaku B and Gerner C: Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy. Breast. 24:532–538. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Ghoneum A, Afify H, Salih Z, Kelly M and Said N: Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. Cancer Med. 7:5047–5056. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M and Buckley CD: A stromal address code defined by fibroblasts. Trends Immunol. 26:150–156. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Tomasek JJ, McRae J, Owens GK and Haaksma CJ: Regulation of alpha-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am J Pathol. 166:1343–1351. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Rodemann HP and Müller GA: Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis. 17:684–686. 1991. View Article : Google Scholar : PubMed/NCBI

23 

Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D and Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA. 99:12877–12882. 2002. View Article : Google Scholar : PubMed/NCBI

24 

Simian M, Hirai Y, Navre M, Werb Z, Lochter A and Bissell MJ: The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development. 128:3117–3131. 2001.PubMed/NCBI

25 

Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD and Rowley DR: Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 8:2912–2923. 2002.PubMed/NCBI

26 

Dotto GP, Weinberg RA and Ariza A: Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci USA. 85:6389–6393. 1988. View Article : Google Scholar : PubMed/NCBI

27 

Castor CW, Wilson SM, Heiss PR and Seidman JC: Activation of lung connective tissue cells in vitro. Am Rev Respir Dis. 120:101–106. 1979.PubMed/NCBI

28 

Müller GA and Rodemann HP: Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am J Kidney Dis. 17:680–683. 1991. View Article : Google Scholar : PubMed/NCBI

29 

Calon A, Tauriello DV and Batlle E: TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol. 25:15–22. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Marsh T, Pietras K and McAllister SS: Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta. 1832:1070–1078. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI

32 

Yáñez-Mó M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA, Aguilera A, Sánchez-Tomero JA, Bajo MA, Alvarez V, et al: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 348:403–413. 2003. View Article : Google Scholar : PubMed/NCBI

33 

Sandoval P, Jiménez-Heffernan JA, Rynne-Vidal Á, Pérez-Lozano ML, Gilsanz Á, Ruiz-Carpio V, Reyes R, García-Bordas J, Stamatakis K, Dotor J, et al: Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol. 231:517–531. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Ishii G, Ochiai A and Neri S: Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev. 99:186–196. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI

36 

Marsh EE, Ekpo GE, Cardozo ER, Brocks M, Dune T and Cohen LS: Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18–30 years old): A pilot study. Fertil Steril. 99:1951–1957. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Bainbridge P: Wound healing and the role of fibroblasts. J Wound Care. 22:407–408, 410-412. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Duffield JS, Lupher M, Thannickal VJ and Wynn TA: Host responses in tissue repair and fibrosis. Annu Rev Pathol. 8:241–276. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Klingberg F, Hinz B and White ES: The myofibroblast matrix: Implications for tissue repair and fibrosis. J Pathol. 229:298–309. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Zeisberg M and Kalluri R: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 304:C216–C225. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 17:1193–1204. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Räsänen K and Vaheri A: Activation of fibroblasts in cancer stroma. Exp Cell Res. 316:2713–2722. 2010. View Article : Google Scholar : PubMed/NCBI

44 

Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S, Guo J, Hu S and Wang Z: Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis. 33:20–29. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Alexander J and Cukierman E: Stromal dynamic reciprocity in cancer: Intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol. 42:80–93. 2016. View Article : Google Scholar : PubMed/NCBI

46 

Lau TS, Chan LK, Wong EC, Hui CW, Sneddon K, Cheung TH, Yim SF, Lee JH, Yeung CS, Chung TK, et al: A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR. Oncogene. 36:3576–3587. 2017. View Article : Google Scholar : PubMed/NCBI

47 

Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, et al: Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol. 242:140–151. 2017. View Article : Google Scholar : PubMed/NCBI

48 

Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, et al: Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71:2455–2465. 2011. View Article : Google Scholar : PubMed/NCBI

49 

Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le Gonidec S, et al: Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73:5657–5668. 2013. View Article : Google Scholar : PubMed/NCBI

50 

Zoico E, Darra E, Rizzatti V, Budui S, Franceschetti G, Mazzali G, Rossi AP, Fantin F, Menegazzi M, Cinti S, et al: Adipocytes WNT5a mediated dedifferentiation: A possible target in pancreatic cancer microenvironment. Oncotarget. 7:20223–20235. 2016. View Article : Google Scholar : PubMed/NCBI

51 

Lawler HM, Underkofler CM, Kern PA, Erickson C, Bredbeck B and Rasouli N: Adipose tissue hypoxia, inflammation, and fibrosis in obese insulin-sensitive and obese insulin-resistant subjects. J Clin Endocrinol Metab. 101:1422–1428. 2016. View Article : Google Scholar : PubMed/NCBI

52 

Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d'Escamard V, Li JR, Hadri L, Fujitani K, et al: Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun. 7:118532016. View Article : Google Scholar : PubMed/NCBI

53 

Madar S, Goldstein I and Rotter V: ‘Cancer associated fibroblasts’--more than meets the eye. Trends Mol Med. 19:447–453. 2013. View Article : Google Scholar : PubMed/NCBI

54 

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ and Mok SC: TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73:5016–5028. 2013. View Article : Google Scholar : PubMed/NCBI

55 

Wang L, Yang D, Tian J, Gao A, Shen Y, Ren X, Li X, Jiang G and Dong T: Tumor necrosis factor receptor 2/AKT and ERK signaling pathways contribute to the switch from fibroblasts to CAFs by progranulin in microenvironment of colorectal cancer. Oncotarget. 8:26323–26333. 2017.PubMed/NCBI

56 

Gomes FG, Nedel F, Alves AM, Nör JE and Tarquinio SB: Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 92:101–107. 2013. View Article : Google Scholar : PubMed/NCBI

57 

Ferrara N: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21:21–26. 2010. View Article : Google Scholar : PubMed/NCBI

58 

Zhang J and Liu J: Tumor stroma as targets for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : PubMed/NCBI

59 

Zhao Q, Gui T, Qian Q, Li L and Shen K: B-cell-specific Moloney murine leukemia virus integration site 1: Potential stratification factor and therapeutic target for epithelial ovarian cancer. OncoTargets Ther. 9:5203–5208. 2016. View Article : Google Scholar

60 

Jeter CR, Yang T, Wang J, Chao HP and Tang DG: Concise Review: NANOG in cancer stem cells and tumor development: An update and outstanding questions. Stem Cells. 33:2381–2390. 2015. View Article : Google Scholar : PubMed/NCBI

61 

Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, et al: Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2:13–25. 2015. View Article : Google Scholar : PubMed/NCBI

62 

Singh RK, Dhadve A, Sakpal A, De A and Ray P: An active IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population. Sci Rep. 6:366122016. View Article : Google Scholar : PubMed/NCBI

63 

Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, et al: Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 6:102042015. View Article : Google Scholar : PubMed/NCBI

64 

Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R and Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 16:544–550. 2010. View Article : Google Scholar : PubMed/NCBI

65 

Zeisberg EM and Zeisberg M: The role of promoter hypermethylation in fibroblast activation and fibrogenesis. J Pathol. 229:264–273. 2013. View Article : Google Scholar : PubMed/NCBI

66 

Jiang L, Gonda TA, Gamble MV, Salas M, Seshan V, Tu S, Twaddell WS, Hegyi P, Lazar G, Steele I, et al: Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 68:9900–9908. 2008. View Article : Google Scholar : PubMed/NCBI

67 

Clayton A, Evans RA, Pettit E, Hallett M, Williams JD and Steadman R: Cellular activation through the ligation of intercellular adhesion molecule-1. J Cell Sci. 111:443–453. 1998.PubMed/NCBI

68 

Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature. 432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI

69 

Mao Y, Keller ET, Garfield DH, Shen K and Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar : PubMed/NCBI

70 

Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A and Savai R: Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 8:48436–48452. 2017.PubMed/NCBI

71 

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A and Vanderkerken K: Cancer associated fibroblasts and tumor growth: Focus on multiple myeloma. Cancers (Basel). 6:1363–1381. 2014. View Article : Google Scholar : PubMed/NCBI

72 

Cho H, Seo Y, Loke KM, Kim SW, Oh SM, Kim JH, Soh J, Kim HS, Lee H, Kim J, et al: Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion. Clin Cancer Res. 24:5407–5421. 2018. View Article : Google Scholar : PubMed/NCBI

73 

LeBleu VS and Kalluri R: A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech. 11:dmm0294472018. View Article : Google Scholar : PubMed/NCBI

74 

Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al: Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 7:279ra412015. View Article : Google Scholar : PubMed/NCBI

75 

Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R and Sahai E: Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell. 27:574–588. 2015. View Article : Google Scholar : PubMed/NCBI

76 

Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M and Takeyama H: Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 110:469–478. 2014. View Article : Google Scholar : PubMed/NCBI

77 

Kato T, Noma K, Ohara T, Kashima H, Katsura Y, Sato H, Komoto S, Katsube R, Ninomiya T, Tazawa H, et al: Cancer-associated fibroblasts affect intratumoral CD8+ and FoxP3+ T cells via IL6 in the tumor microenvironment. Clin Cancer Res. 24:4820–4833. 2018. View Article : Google Scholar : PubMed/NCBI

78 

Hofmeister V, Schrama D and Becker JC: Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother. 57:1–17. 2008. View Article : Google Scholar : PubMed/NCBI

79 

Valero T, Steele S, Neumüller K, Bracher A, Niederleithner H, Pehamberger H, Petzelbauer P and Loewe R: Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. J Invest Dermatol. 130:1087–1094. 2010. View Article : Google Scholar : PubMed/NCBI

80 

Umansky V and Sevko A: Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother. 61:275–282. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sun, W., & Sun, W. (2019). Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer (Review). Oncology Letters, 18, 2173-2178. https://doi.org/10.3892/ol.2019.10587
MLA
Sun, W., Fu, S."Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer (Review)". Oncology Letters 18.3 (2019): 2173-2178.
Chicago
Sun, W., Fu, S."Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer (Review)". Oncology Letters 18, no. 3 (2019): 2173-2178. https://doi.org/10.3892/ol.2019.10587